Targeting protein modifications to treat leukemia
Project 3: Therapeutic inhibition of splicing through inhibition of protein arginine methylation in leukemia
This study is looking at how blocking certain proteins can help kill leukemia cells, and it aims to find out which patients might benefit the most from this treatment to improve their chances of recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10862894 on NIH RePORTER |
What this research studies
This research investigates how inhibiting specific proteins involved in RNA splicing can effectively kill leukemia cells. By focusing on protein arginine methyltransferases (PRMTs), which are crucial for the survival of certain leukemia types, the study aims to identify biomarkers that predict which patients will respond to this treatment. The approach includes both laboratory experiments and potential clinical applications, aiming to improve outcomes for patients with acute leukemia. The research also explores the combined effects of different inhibitors to enhance treatment efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or other forms of leukemia that exhibit spliceosomal mutations.
Not a fit: Patients with leukemia that does not involve spliceosomal mutations or those with other unrelated cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with acute leukemia, particularly those with specific genetic mutations.
How similar studies have performed: Previous studies have shown promising results with similar approaches targeting PRMTs in cancer treatment, indicating potential for success in this research.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Abdel-Wahab, Omar — Sloan-Kettering Inst Can Research
- Study coordinator: Abdel-Wahab, Omar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.